In a report published Friday, Bank of America analyst Gregg Gilbert reiterated a Buy rating on AbbVie ABBV, and raised the price target from $56.00 to $58.00.
In the report, Bank of America noted, “ABBV is unique among the US Major Pharma companies given its significant product concentration (50% of 2012 revenues were generated by a single product, Humira). Despite this, we are bullish on ABBV given its attractive valuation, above-average dividend yield, and the potential for the pipeline to deliver a blockbuster HCV franchise over the medium term. We conservatively include no real contribution from the rest of the pipeline despite the fact that we continue to model robust R&D spend.”
AbbVie closed on Thursday at $51.86.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in